These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11731420)

  • 1. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
    Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
    Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
    Wakeling AE; Valcaccia B
    J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
    Fuchs-Young R; Glasebrook AL; Short LL; Draper MW; Rippy MK; Cole HW; Magee DE; Termine JD; Bryant HU
    Ann N Y Acad Sci; 1995 Jun; 761():355-60. PubMed ID: 7625735
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.
    Bethea CL; Mirkes SJ; Su A; Michelson D
    Psychoneuroendocrinology; 2002 May; 27(4):431-45. PubMed ID: 11911997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
    Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
    Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
    Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
    J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
    Sömjen D; Waisman A; Kaye AM
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
    Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
    Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
    Barkhem T; Andersson-Ross C; Höglund M; Nilsson S
    J Steroid Biochem Mol Biol; 1997 May; 62(1):53-64. PubMed ID: 9366498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
    Dardes RC; Bentrem D; O'Regan RM; Schafer JM; Jordan VC
    Clin Cancer Res; 2001 Dec; 7(12):4149-55. PubMed ID: 11751515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
    Wu L; Tannock IF
    Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
    Suh N; Lamph WW; Glasebrook AL; Grese TA; Palkowitz AD; Williams CR; Risingsong R; Farris MR; Heyman RA; Sporn MB
    Clin Cancer Res; 2002 Oct; 8(10):3270-5. PubMed ID: 12374698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.